Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.54 |
| ▸ | ROCK2 known ✓ | O75116 | 3/20 | 0.37 |
| ▸ | ROCK1 known ✓ | Q13464 | 2/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31430963 | 1.00 | ADRB2 (0.54) | ADRB2PDE2AAPEX1PMP22ROCK2 | |
| SCHEMBL9395164 | 0.97 | ADRB2 (0.56) | ADRB2PDE2AAPEX1PMP22ROCK2 | |
| SCHEMBL1140338 | 0.97 | ADRB2 (0.56) | ADRB2PDE2AAPEX1PMP22ROCK2 | |
| SCHEMBL2391380 | 0.97 | ADRB2 (0.56) | ADRB2PDE2AAPEX1PMP22ROCK2 | |
| Bromide SCHEMBL25272003 | 0.95 | ADRB2 (0.54) | ADRB2PDE2AAPEX1PMP22ROCK2 | |
| SCHEMBL1314596 | 0.83 | ADRB2 (0.72) | ADRB2PDE2AAPEX1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL1923125 | 0.78 | ADRB2 (0.67) | ADRB2PDE2AROCK2ROCK1IDO1 | |
| Hydrochloric Acid SCHEMBL28673897 | 0.78 | ADRB2 (0.67) | ADRB2PDE2AROCK2ROCK1IDO1 | |
| SCHEMBL11086725 | 0.77 | DPP4 (0.36) | ADRB2APEX1ACACBCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5759637 | 0.77 | ALDH1A1 (0.38) | ADRB2APEX1PMP22ACACBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192572-B | Transition metal oxide doped polyimide composite material and preparation method thereof | 陕西普利美材料科技有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-119192572-A | Transition metal oxide doped polyimide composite material and preparation method thereof | 陕西普利美材料科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| CN-119192572-B | Transition metal oxide doped polyimide composite material and preparation method thereof | 陕西普利美材料科技有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-119192572-A | Transition metal oxide doped polyimide composite material and preparation method thereof | 陕西普利美材料科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-12161760-B2 | Implantable particles and related methods | SIGILON THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | SIGILON THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| CN-114222590-A | Compositions, devices and methods for factor VII therapy | 西吉隆医疗股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3946463-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | Sigilon Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113840620-A | Compositions, devices and methods for treating fabry disease | 西吉隆医疗股份有限公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| CN-112203646-A | Implantable particles and related methods | 西吉隆医疗股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-112105612-A | Anti-fibrotic compounds, devices and uses thereof | 西吉隆医疗股份有限公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2020198685-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING FABRY DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| CN-111372612-A | Methods, compositions, and implantable elements comprising viable cells | 西吉隆医疗股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267794-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING FABRY DISEASE | GLA, GAA, GBA1 | ADRB2 3580/4885ROCK2 1409/4885ROCK1 997/4885 |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | ADRB2 1287/4885ROCK2 4436/4885ROCK1 4254/4885 |
| US-12161760-B2 | Implantable particles and related methods | TNNT2, TNNI3, TNNC1 | ADRB2 1287/4885ROCK2 4436/4885ROCK1 4254/4885 |
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | TGFB2, TGFB1, COL2A1 | ADRB2 1319/4885ROCK2 2857/4885ROCK1 2780/4885 |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | MSI2, CXCL12, SOST | ADRB2 4683/4885ROCK2 4759/4885ROCK1 4616/4885 |
| US-20250235409-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | ADRB2 1287/4885ROCK2 4436/4885ROCK1 4254/4885 |
| US-20230123802-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | F7, F13B, F9 | ADRB2 4013/4885ROCK2 607/4885ROCK1 1102/4885 |
| US-12605486-B2 | Afibrotic compounds, devices, and uses thereof | SLC11A2, ARG1, COL2A1 | ADRB2 200/4885ROCK2 1183/4885ROCK1 1444/4885 |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | ALDH1A2, MYOC, PDE6C | ADRB2 3783/4885ROCK2 2344/4885ROCK1 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.